Depemokimab
Based on 1 Customer Validation
Depemokimab (GSK-3511294) is a long-acting anti-IL-5 monoclonal antibody. Depemokimab can be used for research of asthma.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Reinheit : 95.24%
- CAS. Nr.: 2243274-14-6
- Molecular Weight:145.8 kDa
-
Speicherung:Shipping with dry ice
Please store the product under the recommended conditions in the Certificate of Analysis.
Biologische Aktivität
Beschreibung
IC50 & Target
IL-5
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | 2011-05 | PHASE1 |
Anwendung
ELISA, FACS, Functional assay
Verified Bioactivity
-
Immobilized IL-15 Protein, Human can bind Depemokimab. The EC50 for this effect is 96.02 ng/mL.
Product Details
-
CAS. Nr. 2243274-14-6
-
Accession P05113
-
Synonyms GSK-3511294
-
Molecular Weight 145.8 kDa
-
Species Reactivity
Human
-
Conjugated
Unconjugated
-
Isotype
Human IgG1 kappa
-
Recommend Isotype Controls
-
Format
-
Human IgG1 kappa
-
Product Properties
-
Appearance
Liquid
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Reinheit
95.24%
-
Reconstitution
The product can be reconstituted/diluted with sterile PBS or saline.
-
Storage & Stability
Please store the product under the recommended conditions in the Certificate of Analysis.
-
Versand
Shipping with dry ice.
Reinheit & Dokumentation
Verweise
[1]. Calzetta L, et al. Investigational Treatments in Phase I and II Clinical Trials: A Systematic Review in Asthma. Biomedicines. 2022 Sep 19;10(9):2330. [Content Brief]
[2]. Singh D, et al. A Phase 1 study of the long-acting anti-IL-5 monoclonal antibody GSK3511294 in patients with asthma. Br J Clin Pharmacol. 2022 Feb;88(2):702-712. [Content Brief]
Calculators
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)